Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated